{
    "clinical_study": {
        "@rank": "141389", 
        "acronym": "TEMPO", 
        "arm_group": [
            {
                "arm_group_label": "GS-6615 6 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single loading dose of GS-6615 30 mg on Day 1, followed by GS-6615 6 mg daily as maintenance for up to approximately 18 months."
            }, 
            {
                "arm_group_label": "GS-6615 3 mg", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single loading dose of GS-6615 30 mg on Day 1, followed by GS-6615 3 mg daily as maintenance for up to approximately 18 months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive a single loading dose of placebo to match GS-6615 followed by placebo to match GS-6615 once daily for up to approximately 18 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the effect of GS-6615 compared to placebo on the overall\n      occurrence of appropriate implantable cardioverter-defibrillator (ICD)  interventions\n      (antitachycardia pacing [ATP] or shock) in adults with ICD or cardiac resynchronization\n      therapy-defibrillator (CRT-D)."
        }, 
        "brief_title": "Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ventricular Arrhythmia", 
        "condition_browse": {
            "mesh_term": "Arrhythmias, Cardiac"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have an ICD or CRT-D implanted for primary or secondary prevention and at least one\n             ICD intervention for ventricular tachycardia/ventricular fibrillation (VT/VF) [shock\n             or ATP] within 60 days prior to screening or a documented VT/VF episode (prior to\n             implantation) within 60 days prior to screening\n\n          -  Use of highly effective contraception methods if female of childbearing potential or\n             sexually active male\n\n        Exclusion Criteria:\n\n          -  New York Heart Association (NYHA) Class IV heart failure\n\n          -  Myocardial infarction, unstable angina, coronary artery bypass graft (CABG) surgery\n             or percutaneous coronary intervention (PCI) within 4 weeks prior to screening or\n             during the screening period before randomization\n\n          -  Hemodynamically significant primary obstructive valvular disease\n\n          -  History of congenital heart disease\n\n          -  Inherited arrhythmia such as Brugada syndrome. Individuals with long QT syndrome Type\n             3 (LQT-3) or hypertrophic cardiomyopathy (HCM) may be considered.\n\n          -  Individuals who are being considered for cardiac transplantation and are on a cardiac\n             transplant list\n\n          -  History of seizures or epilepsy\n\n          -  Cardiac ablation within 3 months prior to screening or planned cardiac ablation\n             during the study\n\n          -  Severe renal impairment\n\n          -  Abnormal liver function tests\n\n          -  Currently taking Class I and Class III antiarrhythmic drugs; such medications should\n             be discontinued 5 half-lives (or 28 days for chronic use of amiodarone) prior to\n             randomization\n\n          -  Currently taking drugs or products that are strong inhibitors or inducers of CYP3A;\n             such medications should be discontinued 5 half-lives prior to randomization\n\n          -  Currently taking ranolazine; Ranolazine should be discontinued at least 7 days prior\n             to Randomization\n\n          -  Females who are pregnant or are breastfeeding\n\n          -  Individuals with a subcutaneous ICD"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104583", 
            "org_study_id": "GS-US-356-0101", 
            "secondary_id": "2013-004430-15"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GS-6615 6 mg", 
                    "GS-6615 3 mg"
                ], 
                "description": "GS-6615 tablets administered orally", 
                "intervention_name": "GS-6615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo to match GS-6615 tablets administered orally", 
                "intervention_name": "Placebo to match GS-6615", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "VT", 
            "VF", 
            "Ventricular Tachycardia", 
            "Ventricular Fibrillation", 
            "shock", 
            "ATP"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)", 
        "overall_contact": {
            "email": "TEMPO@gilead.com", 
            "last_name": "Gilead Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Ewa Prokopczuk, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Health and Medicines Authority", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Israel: Ministry of Health", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall occurrence (total number) of appropriate ICD interventions (ATP or shock) through Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall occurrence (total number) of appropriate ICD interventions (ATP or shock) through end of study", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 18 months"
            }, 
            {
                "description": "Change in premature ventricular complex (PVC) from baseline will be measured in units of count/24 hours.", 
                "measure": "Change in PVC", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "Change in non-sustained ventricular tachycardia (nsVT) from baseline will be measured in units of number of episodes/24 hours.", 
                "measure": "Change in nsVT", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "measure": "Overall occurrence (total number) of ventricular tachycardia (treated or untreated) through Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Overall occurrence (total number) of ventricular tachycardia (treated or untreated) through the end of the study", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 18 months"
            }, 
            {
                "measure": "Time from randomization to the first occurrence of appropriate ICD interventions (ATP or shock) or cardiovascular (CV) death", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "measure": "Overall occurrence (total number) of electrical storm through Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Overall occurrence (total number) of electrical storm through the end of study", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 18 months"
            }, 
            {
                "measure": "Overall occurrence (total number) of inappropriate ICD interventions through Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Overall occurrence (total number) of inappropriate ICD interventions through the end of the study", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 18 months"
            }, 
            {
                "measure": "Time from randomization to the first occurrence of CV hospitalization, emergency room (ER) visit, or CV death", 
                "safety_issue": "No", 
                "time_frame": "Up to 18 months"
            }, 
            {
                "measure": "Change in left ventricular systolic and diastolic function as assessed by echocardiography", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12 and 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}